Electronic Supplementary Material (ESI) for Physical Chemistry Chemical Physics. This journal is © the Owner Societies 2022

SUPPLEMENTARY MATERIAL (Supporting information)

An Investigation of the Predominant Structure of Antibiotic Azithromycin in Chloroform Solution through NMR and Thermodynamic Analysis

Isabel S. Hernandes^a, Haroldo C. Da Silva^a, Hélio F. Dos Santos^{b,c}, Eloah P. Ávila^c, Mauro V. De Almeida^c, Matheus G. R. Gomes^a, Diego. F. S. Paschoal^d, Wagner B. De Almeida^{a,*}

 ^a Laboratório de Química Computacional e Modelagem Molecular (LQC-MM), Departamento de Química Inorgânica, Instituto de Química, Universidade Federal Fluminense (UFF), Outeiro de São João Batista s/n, Campus do Valonguinho, 24020-141, Centro, Niterói, RJ, Brazil.
^b Núcleo de Estudos em Química Computacional (NEQC)

^c Departamento de Química, ICE, Universidade Federal de Juiz de Fora (UFJF), Campus Universitário, Martelos, Juiz de Fora, MG, 36036-330, Brazil.

^dNQTCM: Núcleo de Química Teórica e Computacional de Macaé, Polo Ajuda, Instituto Multidisciplinar de Química, Centro Multidisciplinar UFRJ-Macaé, Universidade Federal do Rio de Janeiro, Macaé, RJ,

27.971-525, Brazil





Figure S1. ω B97x-D/6-31G(d, p) (PCM-Chloroform) fully optimized structures of azithromycin using as starting point X-Ray cartesian coordinates of enantiomers "A" (C3R-C5S) and "B" (C3S-C5R). Heteroatoms and O-H groups are highlighted to ease visualize conformational differences. All four possible configurations for C3 and C5 carbons atoms were explored.



Figure S2. X-Ray and DFT (ω B97x-D/6-31G(d, p) optimized structures using as input X-Ray cartesian coordinates) torsion angles (°) for enantiomers "A" and "B" of azithromycin. X-Ray data for stereoisomers "A" and "B" are highlighted in the dashed rectangle.

2-I: geometry optimized in the vacuum.

2-II: geometry optimized using the PCM model (chloroform solvent) to include solvent effects.

2-III: PCM-Chloroform optimization including five explicit CHCl3 solvent molecules.



Figure S3. B3LYP/6-31G(d,p)-PCM-Chloroform ¹H NMR spectra for eight Azithromycin DFT fully optimized structures (stereoisomers "A" and "B").

(a) M1-A-C3S-C5S	(b) M2-A-C3R-C5S	(c) M3-A-C3S-C5R	(d) M4-A-C3R-C5R
(e) M1-B-C3S-C5S	(f) M2-B-C3S-C5R	(g) M3-B-C3R-C5S	(h) M4-B-C3R-C5R

Table S1. ω B97x-D/6-31G(d, p) (PCM-Chloroform) optimized O-H bond torsion angles (°) and O-H hydrogen bond distances (Å) for stereoisomers A and B of azithromycin optimized using as input X-Ray structures (cartesian coordinates). Results for geometries optimized in the vacuum, PCM-Chloroform, and including five explicit solvent molecules (5CHCl₃) are reported.

Structures	M2-A VacOPT	M2-A PCMOPT	M2-A PCM-OPT	X-Ray Str.	M2-B VacOPT	M2-B PCMOPT	M2-B PCM-OPT	X-Ray Str.	
			5CHCl3				5CHCl3		
	Stereoisomer "A"				Stereoisomer "B"				
O-H Dihedral Angle (°)									
γı [,] [H-O-C2'-C1']	-51.9	-53.2	-51.3	179.9	-146.7	-149.3	-151.7	-61.1	
γ2' [H-O-C4''-C3'']	-38.6	-43.4	-46.0	-123.6	38.6	36.5	35.1	60.3	
γ ₃ '[H-O-C6-C5]	137.0	124.2	111.8	-58.4	-132.6	-133.9	-126.6	-61.0	
γ4' [H-O-C11-C10]	141.6	146.2	144.8	179.8	87.0	86.0	88.1	65.0	
γ5' [H-O-C12-C11]	37.2	36.8	36.9	55.7	173.0	167.1	-169.7	180.0	
H-bond Distance (Å)									
С2'-ОНО	2.37	2.33	2.33	NO H-Bond	2.38			NO H-Bond	
C2'-OHN	-	-	-	NO H-Bond		2.05	2.03	NO H-Bond	
C4"-OHO	2.09	2.18	2.16	NO H-Bond	2.10	2.07	2.06	NO H-Bond	
C6-OHN	1.77	1.73	1.82	NO H-Bond	1.90	1.72	1.69	2.62	
С11-ОНО	2.00	2.03	1.88	NO H-Bond	1.93	2.01	1.99	2.27	
С12-ОНО	2.11	2.10	2.10	2.21	2.11	NO H-Bond	NO H-Bond	NO H-Bond	

Table S2. Selected X-Ray torsion angles (°) for stereoisomers A and B of azithromycin. Sugar rings and 15-membered macrolide units torsion angles are placed separately.

Structures	Stereoisomer A C3R-C5S			Stereoisomer B C38-C5R					
	Ref. [7] Mon-Hyd	Ref. [39] Di-Hyd	Ref. [41] 2007	Ref. [40] Di-Hyd	Ref. [8]	Ref. [9]	Ref. [36]	Ref. [37]	Ref. [38]
	XR1-A	XR2-A	XR3-A	XR4-B	XR5-B	XR6-B	XR7-B	XR8-B	XR9-B
	Pure AZM	Pure AZM	Pure AZM	Pure AZM		AZM inter	racting with o	other species	
Dihedral Angle (°)	X-Ray Strs. Sugar rings								
φ ₁ [C1'-O-C5-C6]	-124.5	-124.6	-124.3	133.3	130.9	119.4	123.2	100.1	123.4
φ ₂ [C1''-O-C3-C4]	-154.7	-154.2	-153.0	145.2	146.1	144.9	147.3	146.1	142.0
ф _{1b} [C2'-C1'-O-C5]	-162.1	-161.7	-161.3	156.3	169.9	168.2	166.2	-152.6 ª	164.9
ф _{2b} [C2"-C1"-O-C3]	-160.5	-161.3	-163.5	152.5	147.7	153.8	155.3	154.2	149.8
Dihedral Angle (°)	15-Membered Macrocycle								
φ ₁ ' [C4-C5-C6-C7]	71.2	71.1	72.3	-71.9	-81.7	-73.0	-74.7	-69.6	-70.6
φ ₃ '[O-C1-C2-C3]	-125.7	-126.3	-126.4	121.9	125.8	124.5	120.4	121.4	129.7
φ ₄ , [C12-C13-O-C1]	-128.1	-126.2	-127.5	118.8	120.9	116.9	127.7	119.4	122.0
φ ₆ ' [C9-N-C10-C11]	-146.8	-147.5	-145.3	158.5	142.5	142.0	144.9	156.7	132.7

^a This large deviation from the other dihedral angles for enantiomer B causes a short contact between a pair of hydrogen atoms from C6' and C6'' methyl groups (H-H distance 0.72 Å) due to crystal packing effects for structure from Ref. [37]. This is not observed for the other X-Ray structures. Stereoisomer A (free AZM) exhibits larger H-H distances than B (interacting with biological targets).

Table S3. ωB97x-D/6-31G(d, p) (PCM-5CHCl₃) optimized torsion angles (°) for stereoisomers A and B of azithromycin. Sugar rings and 15-membered macrolide unit torsion angles are placed separately. O-H H-bond distances (Å) are given. X-Ray data are also given.

Structures	M2-A PCM-OPT- 5CHCla	X-Ray Str-A ^a Mono-Hyd-Pure	X-Ray Str-A ^b Di-Hyd-Pure	Deviation ^c	M2-B PCM-OPT- 5CHCla	X-Ray Str-B ^d Di-Hyd-Pure	X-Ray Str-B ^e Complexed- Protein	Deviation ^f
	Stereoisomer "A" Stereoisomer "B"							
			Dih	(°): Sugar rings				
φ1[C1'-O-C5-C6]	-132.4	-124.5	-124.6	-7.9	124.8	133.3	130.9	8.5
φ ₂ [C1"-O-C3-C4]	-143.1	-154.7	-154.2	11.6	144.3	145.2	146.1	0.9
φ ₃ [O-C1'-O-C5]	76.8	77.6	77.7	-0.8	-81.2	-84.5	-67.7	-3.3
φ4 [O-C1"-O-C3]	77.8	73.1	72.2	4.7	-76.2	-82.5	-85.1	-6.3
φ _{1a} [O-C5-C6-C7]	-46.8	-51.6	-51.7	4.8	44.3	52.4	39.2	8.1
φ _{2a} [O-C3-C4-C5]	58.8	73.6	74.9	-14.8	-67.1	-59.4	-53.1	7.7
ф1ь [C2'-C1'-O-C5]	-164.6	-162.1	-161.7	-2.5	158.5	156.3	169.9	-2.2
ф _{2b} [C2"-C1"-O-C3]	-155.2	-160.5	-161.3	5.3	157.5	152.5	147.7	-5
			Dihedral A	ngle (°): 15-	-membered m	acrocycle		
φ1' [C4-C5-C6-C7]	78.6	71.2	71.1	7.4	-80.4	-71.9	-81.7	8.5
φ2' [C2-C3-C4-C5]	-178.6	-162.9	-163.2	-15.7	169.8	177.2	-178.5	7.4
φ ₃ '[O-C1-C2-C3]	-115.2	-125.7	-126.3	10.5	124.1	121.9	125.8	-2.2
φ ₄ , [C12-C13-O-C1]	-100.6	-128.1	-126.2	27.5	99.5	118.8	120.9	19.3
φ5' [C10-C11-C12-C13]	-170.5	-156.6	-157.9	-13.9	171.3	161.4	158.6	-9.9
φ6' [C9-N-C10-C11]	-150.4	-146.8	-147.5	-3.6	145.1	158.5	142.5	13.4
			Dihe	edral Angle	(°): O-H Grou	ıps		
γ _{1'} [H-O-C2'-C1']	-51.3	179.9	-0.1	-128.6	57.5	84.2	-61.1	26.7
γ2'[H-O-C4''-C3'']	-46.0	-123.6	-124.4	77.6	37.6	20.8	60.3	-16.8
γ3'[H-O-C6-C5]	111.8	-58.4	-59.9	53.4	-123.6	-118.4	-61.0	5.2
γ4' [H-O-C11-C10]	144.8	179.8	0.7	-35	-144.6	-109.3	65.0	35.3
γ5' [H-O-C12-C11]	36.9	55.7	55/0	-18.8	-38.1	-47.1	180.0	-9
			H-bo	nd Distance	(Å): O-H Gro	oups		
	M2-A	X-Ray Str-A	X-Ray Str-A	-	М2-В	X-Ray Str-B	X-Ray Str-B	-
	PCM-OPT-	Mono-Hyd-	Di-Hyd-Pure		PCM-OPT-	Di-Hyd-Pure	Complexed-	
	5CHCl ₃	Pure			5CHCl ₃		Protein	
C2'-OHO	2.33	3.56	2.50	-	2.43	2.75	NO H-Bond	-
C4" OH O	2.16	(NO H-Bond)	(NO H-Bond)		2.00	(NO H-Bond)	NO LI Dond	
C4 -OHO	2.10	S.05 (NO H-Bond)	(NO H-Bond)	-	2.09	2.22	NO H-BOIR	-
C6-OHN	1.82	3.29	3.28	_	1.76	1.98	2.62	
	1.02	(NO H-Bond)	(NO H-Bond)		1.70	1.70	NO H-Bond	-
С11-ОНО	1.88	3.55	2.96	-	1.84	3.39	2.27	-
		(NO H-Bond)	(NO H-Bond)			(NO H-Bond)		
С12-ОНО	2.10	2.21	2.18	-	2.12	2.20	NO H-Bond	_

^a See Ref. [7]

^b See Ref. [41]

^c Deviation with respect to X-Ray data from Ref. [7]

^d See Ref. [40] ^e See Ref. [8]

^f Deviation with respect to X-Ray data from Ref. [35]



Figure S4. Azithromycin X-Ray structures for stereoisomer A (a,b) and B (c-h) B. Crystallographic data can be found in the references indicated in brackets. There is a short contact between a pair of hydrogen atoms from C6' and C6'' methyl groups (H-H distance 0.72 Å) for structure **XR7-B** due to crystal packing



Figure S5. (a) Radial distribution function -g(r) – between AZM (solute) and CHCl₃ (solvent). The geometric center was used for the solute and H (blue line) or Cl (green line) for CHCl₃. (b) Spatial density map representing the overlap of 5000 frames with one solute and 5 CHCl₃ molecules each. The numbers indicate the most probable regions of each solvent molecule. Only the CH...AZM curve showed a peak centered at ~5 Å, which is due to the fact that CHCl₃ acts as H-donor. The integral of the first peak up to 6.4 Å gave 4 - 5 CHCl₃ molecules on average, which might be assigned as a 'micro solvation-shell'. The second solvation shell extends up to 10 Å and includes 24 solvent molecules. It is notable that the density of molecules is localized in some specific regions, close to the O atoms, which might be used as reference to include explicit solvent molecules.

Experimental Procedure

A sample of solid azithromycin was purchased and later extracted from compounding pharmacy pill. Thinlayer chromatography (TLC) was performed on TLC plates (silica gel 60 F254) and visualized by an ethanolic solution of sulfuric acid (20%), under heating, in order to confirm its purity. The ¹H NMR was measured on a Bruker Avance III HD magnetic resonance spectrometer and was recorded at 500 MHz and ¹³C were recorded at 125 MHz. Chemical shifts were reported as δ (parts per million - ppm) relative to the signals of CDCl₃ at 7.26 ppm (singlet) and 77.0 (triplet) for ¹H and ¹³C, respectively. Tetramethylsilane (TMS) was established as an internal reference. NMR chemical shifts are reported employing the following peak abbreviation pattern: s, singlet; d, doublet; dd, double doublet; t, triplet; tdd, triplet of doublet of doublets; dq, doublet of quartets; dt, doublet or triplet; dqd, a double quartet of doublet; ddd, double double doublet; and m, multiplet.

The ¹H NMR spectrum was deconvoluted with the aim of identifying the most complex signals, as well as identifying the hydroxyl 6-OH. The methyl groups were identified as (Me) and the hydrogen atoms were identified according to **Scheme 1**.

Characterization data for Azithromycin

¹**H NMR** (500 MHz, **CDCl**₃) **δ**: 7.29 (s, 1H, 6-OH)^{*}, 5.18 (d, J = 4.7 Hz, 1H, H-1"), 4.99 (s, 1H, 11-OH), 4.72 (dd, J = 9.8, 2.4 Hz, 1H, H-13), 4.46 (d, J = 7.3 Hz, 1H, H-1"), 4.28 (dd, J = 3.5, 1.9 Hz, 1H, H-3)^{*}, 4.11 (dq, J = 11.9, 6.0 Hz, 1H, H-5"), 3.71 (s, 1H, H-5), 3.67 (d, J = 7.3 Hz, 1H, H-11), 3.54 (tdd, J = 13.0, 6.5, 2.1 Hz, 1H, H-5"), 3.36 (s, 3H Me-8"), 3.27 (dd, J = 10.0, 7.4 Hz, 1H, H-2"), 3.06 (d, J = 8.0 Hz, 1H, H-4")^{*}, 2.99 (s, 1H, 12-OH), 2.73 (m, 1H, H-2)^{*}, 2.73 (m, 1H, H-10)^{*}, 2.56 (d, J = 10.70 Hz, 1H, H-9a), 2.50 (m, 1H, H-3")^{*}, 2.38 (d, J = 15.3 Hz, 1H, H-2"a), 2.34 (s, 3H, Me-20), 2.33 (s, 6H, Me-7", Me-8"), 2.20 (s, 1H, 2"OH)^{*}, 2.12 – 2.01 (m, 3H, H-8, H-9, 4"-OH), 1.98 (qd, 1H, J = 7.5, 1.4 Hz, H-4) 1.92 (dqd, J = 14.8, 7.3, 2.3 Hz, 1H, H-14a)^{*}, 1.81 (d, J = 14.6 Hz, 1H, H-7a), 1.70 (d, J = 11.9 Hz, 1H, H-4"a), 1.61 (dd, J = 15.2, 5.0 Hz, 1H, H-2"b), 1.48 (ddq, J = 14.2, 9.6, 7.2 Hz, 1H, H-14b), 1.37 – 1.30 (m, 7H, Me-18, Me-6", H-7), 1.29 (d, J = 6.4 Hz, 1H, H-4"b), 1.27 (s, 3H, Me-7"), 1.25 (d, J = 6.1 Hz, 3H, Me-6"), 1.21 (d, J = 7.4 Hz, 3H, Me-16), 1.14 – 1.10 (m, 6H, Me-21, Me-22), 1.06 (d, J = 7.5 Hz, 3H, Me-17), 0.93 (d, J = 6.2 Hz, 3H, Me-19), 0.91 (t, J = 7.3 Hz, 3H, Me-15). ¹³C NMR (125 MHz, CDCl₃) **b**:178.78, 102.99, 94.54, 83.46, 78.14, 77.47, 77.44, 74.29, 73.8, 73.67, 72.99, 70.87, 70.08, 68.71, 65.63, 65.48, 62.37, 49.47, 45.29, 42.35, 42.11, 40.34, 35.8, 34.77, 28.82, 27.51, 26.79, 21.67, 21.34, 21.28, 21.20, 18.22, 16.18, 14.82, 11.27, 9.10, 7.33.

* Signals of deconvoluted spectrum

[I
	Ref B	A2	J (A2) / Hz	Multiplicity	Δδ
1'	4.47	4.46	7.30	d	-0.01
2'	3.23	3.27	10.0, 7.4	d	0.04
3'	2.48	2.50	-	m	0.02
4'a	1.69	1.70	11.9	d	0.01
4'b	1.27	1.29	6.4	d	0.02
5'	3.52	3.54	13.0, 6.5, 2.1	tdd	0.02
6'	1.21	1.25	6.10	d	0.04
7'/8'	2.30	2.33	-	s	0.03
1"	5.13	5.18	4.70	d	0.05
2"a	2.39	2.38	15.3	d	-0.01
2"b	1.59	1.61	15.2, 5.0	dd	0.02
4"	3.07	3.06	8.0	d	-0.01
5″	4.12	4.11	11.9, 6.0	dq	-0.01
6"	1.34	1.35	6.40	d	0.01
7"	1.27	1.27	-	s	0
8"	3.34	3.36	-	s	0.02
2	2.76	2.73	-	m	-0.03
3	4.30	4.28	3.5, 1.9	dd	-0.02
4	1.99	1.98	7.5, 1.4	qd	-0.01
5	3.65	3.71	-	s	0.06
7a	1.80	1.81	14.60	d	0.01
7b	1.33	1.35	-	m	0.02
8	2.01	2.05	-	m	0.04
9a	2.55	2.56	10.70	d	0.01
9b	2.09	2.05	-	m	-0.04
10	2.70	2.73	m	-	0.03
11	3.70	3.67	7.30	d	-0.03
13	4.68	4.72	9.8, 2.4	dd	0.04
14a	1.89	1.92	14.8, 7.3, 2.3	dqd	0.03
14b	1.52	1.48	14.6, 9.6, 7.3	ddq	-0.04
15	0.89	0.91	7.30	t	0.02
16	1.19	1.21	7.40	d	0.02
17	1.05	1.06	7.50	d	0.01
18	1.32	1.35	-	m	0.03
19	0.92	0.93	6.20	d	0.01
20	2.32	2.34	-	s	0.02
21	1.08	1.11	-	m	0.03
22	1.09	1.11	-	m	0.02
2'-0H	2.60	2.20	-	S	-0.4
4'' -OH	2.10	2.04	-	s	-0.06
6-0H	9.40	7.29	-	S	-2.11
11-0H	5.20	4.99	-	s	-0.21
12-0H	3.20	2.99	-	S	-0.21

Table S4: Identification and comparison of experimental data with literature data¹

0.81

5.0

5.2

27

4.8





4.2 4.0 f1 (ppm)

33

1.15

4.4

ф

4.6

1.26

3.0

44

1.64

3.2

3.4

동문

3.8

1.59

3.6



Figure S8. Expanded ¹H NMR spectrum of Azithromycin ranging from 3.0 to 0.8 ppm



Figure S9. ¹³C NMR spectrum of Azithromycin (125 MHz, CDCl₃)



Figure S10. COSY contour map of Azithromycin.



Figure S11. NOESY contour map of Azithromycin.



Figure S12. Deconvoluted ¹H NMR spectrum of Azithromycin (500 MHz, CDCl₃).